Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors

被引:11
作者
Ponvilawan, Ben [1 ]
Khan, Abdul Wali [1 ]
Subramanian, Janakiraman [2 ]
Bansal, Dhruv [3 ]
机构
[1] Univ Missouri Kansas City, Sch Med, Dept Internal Med, Kansas City, MO 64108 USA
[2] Inova Schar Canc Inst, Fairfax, VA 22031 USA
[3] Univ Missouri Kansas City, St Lukes Canc Inst, Sch Med, Kansas City, MO 64108 USA
基金
英国科研创新办公室;
关键词
immune checkpoint inhibitor; immunotherapy; immune-related adverse events; irAE; biomarker; LUNG-CANCER PATIENTS; BLOOD-COUNT; NIVOLUMAB; ASSOCIATION; TOXICITY; BLOCKADE; EFFICACY; ANTI-CTLA-4; ANTIBODIES; MELANOMA;
D O I
10.3390/cancers16061225
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Immune-related adverse events (irAEs) are one of the most common complications after cancer treatment caused by immune checkpoint inhibitors (ICIs). We performed an extensive review of the potential tests to predict irAEs in patients who receive ICIs. Approximately 40% of patients who receive ICIs experience irAEs. Despite this, only thyroid function tests are currently in mainstream use for predicting who will experience the adverse effects (namely, thyroid function abnormalities) from ICI treatment. A significant amount of research has paved the way for further potential tests that can be used in the clinic, but none have been meaningfully implemented in clinical practice. Nonetheless, further research on identifying these tests and incorporating them into clinical practice to help predict irAEs for patients with cancer will be significant in the field of ICI therapy.Abstract Immune-related adverse events (irAEs) are the most common complication of immune checkpoint inhibitor (ICI) therapy. With the widespread use of ICIs in patients with solid tumors, up to 40% of the patients develop irAEs within five months of treatment, and 11% develop severe irAEs requiring interventions. A predictive test for irAEs would be a crucial tool for monitoring for complications during and after ICI therapy. We performed an extensive review of potential predictive biomarkers for irAEs in patients who received ICI therapy. Currently, only thyroid-stimulating hormone is utilized in common clinical practice. This is due to the unavailability of commercial tests and unclear predictive values from various studies. Given the lack of single strong predictive biomarkers, some novel approaches using composite scores using genomic, transcriptomics, cytokine levels, or clinical parameters appear appealing. Still, these have yet to be validated and incorporated into clinical practice. Further research conducted to validate the models before implementing them into real-world settings will be of the utmost importance for irAE prediction.
引用
收藏
页数:24
相关论文
共 143 条
[1]   Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors [J].
Abdel-Wahab, Noha ;
Diab, Adi ;
Yu, Robert K. ;
Futreal, Andrew ;
Criswell, Lindsey A. ;
Tayar, Jean H. ;
Dadu, Ramona ;
Shannon, Vickie ;
Shete, Sanjay S. ;
Suarez-Almazor, Maria E. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (07) :1939-1949
[2]   Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy [J].
Abed, Afaf ;
Law, Ngie ;
Calapre, Leslie ;
Lo, Johnny ;
Bhat, Vikas ;
Bowyer, Samantha ;
Millward, Michael ;
Gray, Elin S. .
EUROPEAN JOURNAL OF CANCER, 2022, 172 :98-106
[3]   BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors [J].
Ali, Omar Hasan ;
Bomze, David ;
Ring, Sandra S. ;
Berner, Fiamma ;
Fassler, Mirjam ;
Diem, Stefan ;
Abdou, Marie-Therese ;
Hammers, Christoph ;
Emtenani, Shirin ;
Braun, Anne ;
Cozzio, Antonio ;
Mani, Bernhard ;
Jochum, Wolfram ;
Schmidt, Enno ;
Zillikens, Detlef ;
Sadik, Christian D. ;
Flatz, Lukas .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (04) :854-861
[4]   Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors [J].
Ali, Omar Hasan ;
Berner, Fiamma ;
Bomze, David ;
Fassler, Mirjam ;
Diem, Stefan ;
Cozzio, Antonio ;
Jorger, Markus ;
Fruh, Martin ;
Driessen, Christoph ;
Lenz, Tobias L. ;
Flatz, Lukas .
EUROPEAN JOURNAL OF CANCER, 2019, 107 :8-14
[5]   Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events [J].
Alserawan, Leticia ;
Anguera, Georgia ;
Zamora Atenza, Carlos ;
Serra Lopez, Jorgina ;
Martinez-Martinez, Laura ;
Riudavets Melia, Mariona ;
Sullivan, Ivana ;
Barba Joaquin, Andres ;
Majem Tarruella, Margarita ;
Vidal, Silvia .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (20)
[6]   Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment [J].
Alturki, Norah A. A. .
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (13)
[7]   Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events [J].
Bai, Rilan ;
Chen, Naifei ;
Chen, Xiao ;
Li, Lingyu ;
Song, Wei ;
Li, Wei ;
Zhao, Yuguang ;
Zhang, Yongfei ;
Han, Fujun ;
Lyu, Zheng ;
Cui, Jiuwei .
CANCER BIOLOGY & MEDICINE, 2021, 18 (04) :1118-1133
[8]   Immunotherapy-induced thyroid dysfunction: an updated review [J].
Baraka, Bahaaeldin ;
Abosheaishaa, Hazem ;
Nassar, Mahmoud .
EGYPTIAN JOURNAL OF INTERNAL MEDICINE, 2023, 35 (01)
[9]   Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study [J].
Barth, Dominik A. ;
Stanzer, Stefanie ;
Spiegelberg, Jasmin ;
Bauernhofer, Thomas ;
Absenger, Gudrun ;
Posch, Florian ;
Lipp, Rainer ;
Halm, Michael ;
Szkandera, Joanna ;
Balic, Marija ;
Gerger, Armin ;
Smolle, Maria A. ;
Hutterer, Georg C. ;
Klec, Christiane ;
Jost, Philipp J. ;
Kargl, Julia ;
Stradner, Martin ;
Pichler, Martin .
CANCER MEDICINE, 2022, 11 (16) :3074-3083
[10]   Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients [J].
Bins, Sander ;
Basak, Edwin A. ;
el Bouazzaoui, Samira ;
Koolen, Stijn L. W. ;
Hoop, E. Oomen-de ;
van der Leest, Cor H. ;
van der Veldt, Astrid A. M. ;
Sleijfer, Stefan ;
Debets, Reno ;
van Schaik, Ron H. N. ;
Aerts, Joachim G. J. V. ;
Mathijssen, Ron H. J. .
BRITISH JOURNAL OF CANCER, 2018, 118 (10) :1296-1301